Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025EMBO Molecular MedicineOpen Access

Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid

View Full Paper
Ask AI
Bookmark
Share

Authors

NMNiklas MattssonSJShorena JanelidzeOHOskar Hansson

Discussion

Loading...

Member takes

Overview

Analysis using cerebrospinal fluid and β-amyloid predicts amyloid levels in Alzheimer disease, suggesting effective biomarker utility.

Key Points

  • Continuous amyloid levels predicted using cerebrospinal fluid biomarkers and machine learning.
  • Top models reached 0.79 accuracy, improving predictions for Alzheimer disease.
  • Machine learning pipeline effectively utilizes cerebrospinal fluid alongside β-amyloid levels.
  • Highlights the potential of biomarkers in identifying Alzheimer disease pathology.

Cite This Study

Mattsson et al. (2025) studied this question.

synapsesocial.com/papers/6930dc92ea1aef094cca2a73https://doi.org/10.1038/s44321-025-00348-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease2025 · 27 citations
  2. 2Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles2025
  3. 3Accurate and robust prediction of Amyloid-β brain deposition from plasma biomarkers and clinical information using machine learning2025
  4. 4Predictive Value of Plasma Biomarkers in Tau‐<scp>PET</scp> Transitions2025
  5. 5Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals2025